| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 15,286,399 | 17,130,286 | ||
| Prepaid expenses and other current assets | 1,902,562 | 4,324,285 | ||
| Total assets | 17,188,961 | 21,454,571 | ||
| Accounts payable | 2,112,026 | 974,311 | ||
| Accrued expenses | 1,621,771 | 1,830,813 | ||
| Total current liabilities | 3,733,797 | 2,805,124 | ||
| Warrant liability | 299,000 | 319,000 | ||
| Total liabilities | 4,032,797 | 3,124,124 | ||
| Common stock - 0.0001 par value, 70,000,000 shares authorized, 20,187,904 and 14,141,521 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 2,019 | 1,948 | ||
| Additional paid-in capital | 167,023,392 | 164,935,088 | ||
| Accumulated deficit | -153,869,247 | -146,606,589 | ||
| Total stockholders' equity | 13,156,164 | 18,330,447 | ||
| Total liabilities and stockholders' equity | 17,188,961 | 21,454,571 | ||
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)